Category: Patients

The Amyloidosis Forum – bringing together the AL amyloidosis community with FDA
ARC is excited to announce the inaugural gathering of The Amyloidosis Forum on November 12, 2019 at FDA’s White Oak Campus in Silver Spring, MD. (more…)
Read More
ARC Developing a Disease-Specific PRO Tool for Patients with ATTR Amyloidosis
ARC is developing a patient-reported outcome (PRO) measurement tool in ATTR amyloidosis to be used to understand and measure the impact of the disease on patients from the patient’s perspective. (more…)
Read More
Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA
This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)
Read More
Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases
I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...
Read More
New MAP Feature: Treatment Center Comparator
Finding the best amyloidosis care is not easy, so in 2017 ARC created My Amyloidosis Pathfinder (MAP) to help you discover, learn about, and contact treatment centers and clinical trials that are right for you. Now MAP can do even more. (more…)
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org

ARC is a 501(c)(3) nonprofit organization